Status:
COMPLETED
Evaluating Preventive Therapy With Oint Threolone, Synthomycine or Aqua Cream, for EGFR'I Induced Acneiform Rash
Lead Sponsor:
Rabin Medical Center
Conditions:
Acneiform Rash
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The investigators hypothesized that topical anti-inflammatory treatment could counteract the inflammatory reaction induced by EGFR'Is.
Detailed Description
The investigators hypothesized that topical anti-inflammatory treatment could counteract the inflammatory reaction induced by EGFR'Is.
Eligibility Criteria
Inclusion
- Patients who are planed to initiate treatment with either cetuximab , erlotinib, gefitinib or panitumumab.
Exclusion
- Patients who received any facial topical treatment / systemic antibiotics or any anti-inflammatory drug during the 2 weeks prior to study initiation.
- Known hypersensitivity to ointment Synthomycine or to Threolone.
- Patients presented with cutaneous rash during the 2 weeks prior to study initiation
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT01256437
Start Date
January 1 2011
End Date
March 1 2017
Last Update
May 9 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Davidoff Center, Rabin Medical Center, Beilinson
Petah Tikva, Israel, Israel, 49100